ArriVent BioPharma, Inc. - 8-K Filing
ArriVent BioPharma reported $326.4 million in cash and investments as of March 31, 2026, with projected runway into Q4 2027. The company used $41.9 million in net operating cash during the first quarter compared to $68.0 million in the same period last year. R&D expenses were $37.6 million versus $61.3 million a year ago, while G&A costs rose slightly to $8.5 million from $5.5 million. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $AVBP